AbbVie and Iambic have joined forces for an extensive collaboration in order to use artificial intelligence for the discovery of small-molecule drugs. The collaboration involves the molecular superintelligence platform by Iambic and the pharmaceutical capabilities of AbbVie in terms of immunology, neuroscience, and oncology.
The collaboration was announced on September 21, 2026. This is an indication of the increasing importance of artificial intelligence in the development of new medicines. As part of the collaboration, the partners will develop small-molecule drugs that have the ability to become the first or best in class while using artificial intelligence in drug evaluation and identification. The collaboration will not entail the usage of AI at one particular stage of research but in evaluating various features of the potential drugs.
AbbVie Expands Its Use of AI in Drug Discovery
As for pharmaceutical companies, there is a need to test many different molecules according to many different biological and chemical criteria when it comes to early-stage drug discovery. There are certain criteria, such as the potency of the molecule, its selectivity, safety, pharmacokinetic properties, and others that researchers need to take into account before moving towards developing the molecule. It is important to use artificial intelligence to analyze big data and predict properties of molecules in order to determine that worth exploring further.
Thus, the collaboration with Iambic fits well into AbbVie's strategy known as AI@AbbVie. According to AbbVie, AI is being used as an enabler of scientific innovation and decision-making.
Specifically, AbbVie partners with Iambic in order to discover and develop small molecule therapies.
Iambic Brings Molecular Superintelligence to the Collaboration
Iambic's technology platform combines AI with automated chemistry and biology experimentation.
The collaboration will use Enchant v3, the next generation of multimodal transformer model by Iambic. As per the claims made by the two companies, the system uses biomedical data throughout the different stages of drug discovery process and enables multiple hypotheses of drug design to be tested simultaneously. The model uses over 6,000 molecular properties. The Iambic's platform includes Enchant and NeuralPLexer, which are multimodal endpoint predictors across the drug discovery and development process.
The aim is not to test each individual property of the molecule separately. This is because the combination of multiple properties helps in determining the best combination using AI systems.
This becomes important during small-molecule discovery because improvements in any one characteristic may lead to trade-offs in other characteristics.
Immunology, Neuroscience and Oncology Are Key Focus Areas
The partnership is expected to focus on three primary therapeutic fields, including immunology, neuroscience, and oncology.
Such therapeutic fields play a significant role in the development of innovative drugs and involve complicated biological processes that might need a lot of studies in the discovery stage. The objective of using Iambic’s technology combined with AbbVie’s expertise in such fields is to discover first or best-in-class drugs.
AI Could Change How Pharmaceutical Researchers Evaluate Molecules
Discovery of traditional small-molecules may need a lot of properties to be considered by the researchers in order for the research process to be done. Iambic’s technology aims at evaluation of various properties at once, giving room for researchers to develop and test more hypothesis at once.
According to Dr. Nicholas Donoghoe, AbbVie executive vice president and chief business and strategy officer, the company believes that the use of artificial intelligence will catalyze scientific innovation and the company is going to ensure that the discovery scientists are equipped with tools that will help in their research processes.
This is important since artificial intelligence has been introduced in scientific processes without the intention of replacing the researchers but rather assisting them in analyzing data and making decisions on what molecules to study.
Drug Discovery Partnerships Are Moving Beyond Generic AI
The AbbVie-Iambic agreement also highlights a broader change in pharmaceutical AI partnerships.
Earlier efforts to leverage AI in life sciences generally entailed isolated use cases like analysis, target identification, or clinical trial assistance. More recently, pharmaceutical firms have started to collaborate with AI firms that create platforms designed expressly for molecular design and drug discovery. Dedicated solutions allow the incorporation of specific biological and chemical information as opposed to just AI algorithms.
The Iambic Enchant v3 platform is one such solution. It is built on biomedical data and molecular characteristics relevant to the field of pharmaceuticals. In case of big pharma organizations, such collaborations ensure that firms gain access to dedicated technology but maintain control over therapeutic approaches and strategies.
AbbVie Is Building a Broader AI Strategy
The Iambic collaboration is not an isolated AI initiative for AbbVie.
Another AI partnership for the company was declared on September 29, 2026, with Valkai, where the aim is to make use of AI capabilities in the selected areas of clinical development. The partnership is expected to help AbbVie to increase efficiency in its research work, speed up the process of gaining insights, and offer options to decrease development time.
Overall, both partnerships show how the company is making use of AI not only in discovery but also at other stages of pharmaceutical development. The first collaboration is focused on discovery, while the latter is related to certain areas of clinical development.
The Economics of AI-Driven Drug Discovery
Evaluating more options prior to investment in laboratory testing is one of the biggest possible benefits that can be provided by AI in drug discovery. Despite all the advancements, the process of developing drugs continues to be long and complicated, and not all drug candidates go on to make successful products. AI technology cannot reduce biological uncertainties, but it may help researchers choose which candidates to invest in and which hypotheses to test.
The partnership between AbbVie and Iambic is important not because it ensures faster drug development, but rather because it is a way to apply computational power to facilitate decision making at the early stages of discovery. Nevertheless, further validation of predictions made with the help of AI will still have to take place in laboratories.
What the AbbVie-Iambic Partnership Means for Pharmaceutical AI
This collaboration shows how artificial intelligence is being increasingly used in pharmaceutical research. While AbbVie can contribute to the field because of its therapeutic knowledge, Iambic brings to the table its artificial intelligence and molecular design technology. This can enable the two firms to explore their drug candidates through a highly data-driven process of discovery.
"Through this collaboration we will aim to harness our technology in combination with AbbVie's scientific team to address areas of unmet patient need," commented Iambic co-founder and CEO Tom Miller, Ph.D. The agreement stipulates that Iambic will be paid upfront, and be entitled to success-based milestone payments and tiered royalty payments from any resulting product net sales.
Outlook for AI-Driven Drug Discovery
The collaboration between AbbVie and Iambic comes at a time when pharmaceutical firms are increasingly turning to AI-specific technology to boost their research efficiency and drug development process. The trend is moving away from the application of AI for administrative or analytical purposes to the deployment of AI-specific models for solving scientific challenges ranging from molecule design, property prediction, target discovery, and development.
From AbbVie's perspective, the collaboration provides an additional element to its growing AI portfolio. From Iambic's perspective, the collaboration allows the use of its molecular superintelligence technology in combination with discovery expertise from one of the leading pharmaceutical firms. How the long-term benefit will be achieved remains to be seen in terms of translating the insights generated via AI into successful drugs that pass through research and clinical development stages.
